“We’ll become a company leading the obesity market within 10 years”

The obesity rate has finally exceeded 37% for adults over 30 in Korea, which means 1 of 3 adults are obese. Thus, Novo Nordisk, a global pharmaceutical company, has launched Saxenda(generic name: liraglutide 3.0mg), a glucagon-like peptide 1, for the first time in Asia on the 16^th of March.

Approval & Clinical Study Vice President Yan Cai, International Operation Officer at Novo Nordisk who vi...